Donanemab: Appropriate use recommendations

Rabinovici, G D; Selkoe, D. J.; Schindler, Suzanne E.; Aisen, Paul; Apostolova, Liana G.; Atri, Alireza; Greenberg, Steven M.; Hendrix, Suzanne; Petersen, R.C.; Weiner, Myron; Salloway, Steve; Cummings, Jeffrey L.

doi:10.1016/j.tjpad.2025.100150

articleThe Journal of Prevention of Alzheimer s DiseaseMar 30, 2025DIAMOND OA

Donanemab: Appropriate use recommendations

GDG D Rabinovici DJD. J. Selkoe SESuzanne E. Schindler PAPaul Aisen LGLiana G. Apostolova

University of California, San Francisco · University Memory and Aging Center · +14 more institutions

PubMed

Indexed incrossrefdoajpubmed

Abstract

Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). Appropriate Use Recommendations (AUR) were developed to guide the implementation of donanemab in real-world practice, prioritizing safety considerations and opportunity for effectiveness. The AUR were developed by the AD and Related Disorders Therapeutic Workgroup by consensus, integrating available data and expert opinion. Appropriate candidates for donanemab treatment include persons with mild cognitive impairment or mild dementia due to AD (Clinical Stages 3-4, MMSE 20-30) who have biomarker…

Citation impact

143

total citations

FWCI: 154.79
Percentile: 100%
References: 95

Citations per year

Authors

12

Topics & keywords

Topics

Keywords

Medicine

No related works found for this paper.